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SUMMARY
LV dysfunction is a common complication oí myocardial infarction. The degree oí LV
dysfínction is positively correlated to increasing cardiac mortality. Cardiac mortality
ií patients wltir w dysiunction can be subdivided into 2 modalit ies: progressive CHF
and sudden death. This thesis deals with the risk of sudden death in patients with LV
àysíunction. Apart from a reduced pumping Íunction of the LV several other factors
occuring during the development of cHF are Potentially arrhythmogenic' These
include LV dilatation, neurohormonal activation and the Presence oí ventricular
arrhythmias, either spontaneous or induced. Treatment oí these Patients is primarily
aimed at preservation of LV function and prevention of arrhythmias, neurohormonal
activation and ischemia. This thesis describes the Patient at high risk for sudden
death, who can be idenrif ied by studying LV function and volume, neurohormonal
status and vulnerabil ity íor ventricular arihythmias (appendices l-5). Several kinds oí
intervention were studied as probes to investigate the multifactorial effects of phar-
macological intervention in patients with LV dysfunction. These are described in
appendices 6-10.
In appendix | , the roles of the risk factors LV dysfunction, Presence of arrhythmias
and lschemia are reevaluated in view of the thrombolytic era. This report shows that
successful thrombolytic theraPy improves survival after myocardial infarction' lf
patency is obtained, it favorably afíects two important risk íactors. Both LV function
and electrical stability are pre;erved by, in particular early, but also late patency oí
the infarct,related artery. consequently, the development oí two high risk factors
after myocardial infarction is at least in part prevented' The third risk Íactor' recur-
rent myocardial ischemia or reiníarction, does not seem to be favorably affected by
thromÉolytic intervention. On the contrary' the reinfarction rate is increased by
early thrombolytic therapy. The value of diagnostic tests remains unchanged after
thrombolysis. Niew risk factors are non-patency and abnormal autonomic control '
The relation between two important risk factors after myocardial infarction' LV dila-
tation and HR variabil ity, is described in appendices 2 and 3' After anterior
infarction, recovery of Hí\ variability parameters was most marked in patients who
did not have increasing LV volume. By contrast, HR variabil ity in dilators hardly im-
proved, which was mást clearly seen in the day-time hours. The identification of
both higher concentrations oí plasma norepinephrine before dilatation, and the re-
ductioriin day-time HR variability recovery in the dilating SrouP suSSest at least a
contributing iole of the autonomic nervous system in the develoPment oí LV dilata-
tion. The simpathetic nervous system remains activated after the infarct in Patients
with dilating LV.
Appendix 4 describes howvTs develop during conditions of 
_altered autonomic
.ontrot, i.e. physical exercise. In a total cardiologic population oÍ 5942 Patients, sixty
( 1.0%) patients developed I 94 episodes ofvT during exercise stress testing. Forty-

















































































ent init iating electrocardiographic patterns were observed. In l7 (28%) patientsVT
was init iated by a short-long-short sequence of R-R intervals (group l). Thirty-eight
(63%) patients did not have this pattern oÍ interval changes precedingVT (group 2).
Five (8%) other patients showed both patterns. Clinical characteristics oíthe groups
were diÍíerent for angina and cardiomyopathy but not for previous myocardial
infarction. In group l,VT was related to recovery (76%;p<0.05). In group 2, occur-
rence of VT was equally divided between exercise and recovery.The electrocardio-
graphic differences uggested that different init iating mechanisms are involved in the
development oÍ exercise-induced Vï which may enhance aimed antiarrhythmic
therapy.
Appendix 5 reviews the value of HR variabil ity analysis in patients with LV dysfunc-
tion. HR variabil ity appeared closely related to the degree of neurohormonal activa-
tion and, to a lesser extent, to hemodynamic variables. Cardiovascular drugs may
either stimulate or inhibit the degree of neurohumoral activation, and the effects of
drug treatment on HR variabil ity were in teneral consistent with their long-term
effects in LV dysfunction and CHE
In appendices ó and 7, two novel antiarrhythmic drugs are studied in the context
of LV dysfunction. The first, the class lC antiarrhythmic restacorin, did not affect
hemodynamics in normal subjects, whereas in patients with LV dysfunction, a rel-
evant worsening of hemodynamic parameters was observed. The second, the class
ll l  antiarrhythmíc almokalant, did not cause autonomic changes in postinÍarct sub-
jects. Almokalant prolonged refractory periods and action potential duration, in
particular at shorter pacing cycle lengths. The results also indicated absence of re-
verse rate-dependence. Therefore, our study confirmed that class I drugs are inap-
propriate in LV dysfunction. Class l l l  agents appear more successful in LV dysfunc-
tion, although the clinically adverse proarrhythmic effects should be solved first, be-
fore widespread use of these agents can be recommended.
Appendix 8 describes the effect oí acute hemodynamic improvement in patients
with severe CHE Treatment with a single dose of isomazole not only improved
hemodynamics, but also improved HR variabil ity. This study sugtests that impaired
autonomic cardiac control can be acutely improved by correcting hemodynamic ab-
normalities. Long-term effects of this drug can not be predicted or extrapolated
from thls study.
For twenty years, the beneficial effect of B-blockers on sudden death rate after
myocardial infarction is well known. Appendix 9 details the relevance of l ipophil i-
city of B-blockers. Previously, it has been reported that effects of B-blockers may be
mediated by a central effect. Central administration of these drugs increased the
threshold forVE lí this were true, it would change the concept of postinfarct reat-
ment with B-blockers. ln appendix 9 is described that l ipophil ic metoprolol acts simi-
larly to hydrophil ic atenolol with respect o HR variabil ity. Not only during rest, but
also during challenges such as physical exercise and mental load,both drugs behaved
5 7
C r e p r r p .  l V
the same. compared to the drugíree Period, both drugs increased HR variabil ity
during daily l i fe and mental load. ihis shows that during normal daily l i fe, the addi-
tionaieffeét of l ipophil icity of B-blockers is not apparent. Whether this also holds
for conditions l ike emotional stress or acute ischemia needs to be investigated.
Angiotensin-converting enzyme inhibitors are widely used in Patients with LV dys-
funïtion. Prognosis oflhese Patients is improved with AcE-inhibitors' This holds
true particulirly íor prevention of progression of CHE Since the effects of ACE-
inhibitors on sudden death are less convincing, in appendix | 0 we studied the ef-
fect of the ACE-inhibitor perindopril on the arrhythmia risk proíi le in .Patients with
LV dysíunction after myocardial infarction. After 3 months treatment,the LV volume
in párindopril patients had not increased, whereas in the placebo grouP it had in-
.re"red signiÍicantly. Thus, perindopril prevented the occurrence of LV dilation after
myocardia-í infarction. Arterial blood pressure was decreased in the patients with
pÉrindopril. Norepinephrine levels were equal. The beneficial effect of preservation
of LV function was paralleled by an improved arrhythmia risk profi le. sustained ar-
rhythmias in the perindopril group were induced at a later stage during the protocol'
lnduct ion ofVF was lower i r i the per indopr i l  group:  12%vs.3 l%,but  d id not  reach
significance. Effective reíractory periods in perindopril patients were slightly but
cànsistently longer during all stages. Dispersion of refractoriness was significantly
higher in iíducib-le patienË and wás lower in the perindopllEPyP'25+l7ms in the
plïcebo group and l7Í | lms in the perindopril group (p<0'05), From this study we
conclude that chronic treatment with perindopril has mild direct antiarrhythmic
properties in postinfarct patients with LV dysfunction. The antiarrhythmic effect was
reflected by a reduction in induction oíVF, a prolongation oí the effective refractory
periods aíd particularly a reduced dispersion of reÍractoriness. This effect of
perindopril may contribute to a more homogeneous electrical circuit,which can be
expected to improve Prognosis.
coNcLUSIONS
The aims of the thesis were to identify the high risk conditions for sudden death and
to investigate the effects of intervention,focusing on the interplay between LV dys-
function and neurohormonal activity. The patient at hiSh risk for sudden death has
an importantly impaired LV function and a dilated LV, which forms a Potential sub-
strate for arrhythmias. Sustained changes in neurohormonal control (low HR vari-
ability) are an important modulating factor. After myocardial infarction, the patient
at risk can already be identif ied by a sustained low HR variabil ity that does not im-
prove during follow-up. This is paralleled by dilation of the LV In the subacute phase,
norepinephiine concentration in this patient is generally high compared to the pa-
tient in whom autonomic control is restored during follow-up. Effects oí interven-
tion can be assessed by close monitoring of HR variabil ity. Drugs of which it is
known that they improve long-term prognosis increase HR variability and vice versa'
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The most relevant pharmacological intervention in patients with LV dysfunction is
treatment with ACE-inhibitors. This thesis shows not only that treatment with
perindopril preserves LV function, but also that the arrhythmia risk proíi le is
favorably affected. B-Blocking agents are known íor their favorable effect on sudden
death rate in the postinfarct setting. The mechanism for this effect is not completely
understood, but central effects of B-blockers still may play a role, despite the íact
that we could not demonstrate a diíÍerential effect between lipophilic and hydro-
phil ic agents. Differences may occur in particular during conditions l ike emotional
stress and acute ischemia. Antiarrhythmics of class l l l , such as amiodarone and
sotalol may be promising in LV dysfunction. Novel class l l l  agents induce neither
decline of LV function nor alterations in autonomic functions. Nevertheless, similar
to classlagents,pure class l l l  drugs have been shown recentlyto increase mortality
in postinfarct patients with LV dysfunction.
Future pharmacological intervention in patients with LV dysfunction should take
into account the multiíactorial effects of drugs. ln order to safely obtain preserva-
tion of LV function and prevention arrhythmias, new drugs for this indication should
be studied in subjects with - at least - LV dysÍunction. Then, hemodynamic and
neurohormonal effects should be closely monitored. Future studies should assess
whether l ipophil icity is a relevant property of B-blockers during emotional stress or
acute ischemia, with respect to occurrence of VF. Moreoven combinations of ACE-
inhib i tors,  B-b lockers and possib ly  c lass l l l  a tents may fur ther  improve the
arrhythmia risk profile in LV dysfunction.
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